Molnupiravir | Remdesivir | ||
---|---|---|---|
(n = 57) | (n = 16) | ||
Age, median (range) | 55 (19–74) | 62 (27–74) | |
Gender, n (%) | |||
Male | 36 (63) | 7 (44) | |
Female | 21 (37) | 9 (56) | |
Hospitalization, n (%) | 9 (16) | 16 (100) | |
Disease progression, n (%) | 8 (14) | 2 (13) | |
Adverse events, n (%) | 1 (2) | 4 (25) | |
Liver dysfunction ( ≦ G2) | ― | 3 (19) | |
Acute kidney injury (Stage 1) | 1 (2) | 1 (6) |